Recommended Products
biological source
mouse
Quality Level
100
500
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
MRQ-7, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (357M-14)
vial of 0.5 mL concentrate (357M-15)
bottle of 1.0 mL predilute (357M-17)
vial of 1.0 mL concentrate (357M-16)
bottle of 7.0 mL predilute (357M-18)
manufacturer/tradename
Cell Marque™
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
isotype
IgG
control
B-cell lymphoma, tonsil
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic, nuclear
Gene Information
human ... TCL1A(8115)
Related Categories
General description
T-cell leukemia/lymphoma protein 1 (TCL1, TCL1A, p14TCL1) is a 14 kDa product of the TCL1 gene that is involved in T-cell prolymphocytic leukemia (T-PLL). TCL1 protein is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 binds to a novel site in the pleckstrin homology (PH) domain, resulting in activation and nuclear translocation of Akt by overexpressed TCL1 which may promote an anti-apoptotic response; this may normally serve to promote growth during development but may lead to malignancy when TCL1 is overexpressed. TCL1 is expressed in differentiated B-cells under both reactive and neoplastic conditions, antigen committed B-cells, and in germinal center B-cells. TCL1 is down-regulated in the latest stage of B-cell differentiation. TCL1 is overexpressed in Burkitt lymphoma, the majority of AIDS-related non-Hodgkin lymphoma-designated immunoblastic plasmacytoid lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and primary cutaneous B-cell lymphoma. Therefore, the most useful application of anti-TCL1 is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma.
Quality
 IVD |  IVD |  IVD |  RUO |
Linkage
TCL1 Positive Control Slides, Product No. 357S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M G Narducci et al.
Cancer research, 60(8), 2095-2100 (2000-04-29)
Chromosomal rearrangements observed in T-cell prolymphocytic leukemia involve the translocation of one T-cell receptor gene to either chromosome 14q32 or Xq28, deregulating the expression of cellular protooncogenes of unknown function, such as TCL1 or its homologue, MTCP1. In the human
J Roos et al.
Pathobiology : journal of immunopathology, molecular and cellular biology, 69(2), 59-66 (2001-12-26)
TCL1, MTCP1 and TCL1b are three members of a new family of oncogenes that are expressed in T cell leukemias of ataxia telangiectasia patients (T-PLL, T-CLL). TCL1 is located at 14q32.1 and activated by juxtaposition to the alpha/delta-locus at 14q11
E Pescarmona et al.
Histopathology, 49(4), 343-348 (2006-09-19)
To investigate by immunohistochemical analysis the expression of the TCL1 oncogene product and of CD27 in 25 cases of primary cutaneous B-cell lymphomas (PCBCL) classified according to the World Health Organization-European Organization for Research and Treatment of Cancer classification of
Yuri Pekarsky et al.
Hematology/oncology clinics of North America, 18(4), 863-879 (2004-08-25)
Mature leukemias and lymphomas are a heterogeneous group of lymphoproliferative neoplasias characterized by the accumulation of mature lymphocytes in lymph nodes, other lymphoid tissues, and peripheral blood. In this article we discuss molecular mechanisms leading to the pathogenesis of two
Scott J Rodig et al.
The American journal of surgical pathology, 32(1), 113-122 (2007-12-29)
The distinction between Burkitt (BL) or atypical Burkitt/Burkitt-like lymphomas harboring a MYC translocation (MYC+) and diffuse large B-cell lymphomas (DLBCLs) with high proliferation fractions but without a MYC translocation (MYC-) can be difficult using standard morphologic and immunohistochemical criteria. Recently
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service